Haematology Maximising the value and performance of CSL’s existing coagulation therapies and developing new therapies for bleeding disorders and other benign haematologic conditions PRODUCT TYPE COUNTRY/REGION ALBURX® Human Albumin NR Indonesia (20%), Pakistan (25%) AFSTYLA® Coagulation Factor VIII (Recombinant) NR Indonesia (500, 1000, 2000 IU), South Africa (250, 500, 1000, 1500, 2000, 2500 & 3500 IU) HEMGENIX® Recombinant adeno-associated viral vector with codon-optimised Padua derivative of Human Factor IX cDNA NR United Arab Emirates HAEMATE® Coagulation Factor VIII/vWF (Human) NR Egypt (250/600, 500/1200IU), South Africa (250/600, 500/1200, 1000/2400 IU) IDELVION® Coagulation Factor IX (Recombinant) Albumin Fusion Protein NR Guatemala (500 IU), South Africa (250, 500, 1000, 2000, 3000 IU) RiaSTAP® Fibrinogen Concentrate (AFD) NR European Union Vaccines Developing products for the prevention of infectious disease PRODUCT TYPE COUNTRY/REGION AUDENZ®/ INCELLIPAN® Influenza Vaccine Pandemic Monovalent (Surface antigen, Inactivated, Cell-Based, Adjuvanted) NR New Zealand, Singapore, Switzerland AUJEMFLU® Influenza Vaccine Seasonal Trivalent (Surface antigen, Inactivated, CellBased, Adjuvanted) NR United Kingdom CELLDEMIC® Influenza Vaccine Zoonotic Monovalent (Surface antigen, Inactivated, Cell-Based, Adjuvanted) NR New Zealand, Singapore, Switzerland FLUCELVAX® Influenza Vaccine Seasonal Trivalent (Surface antigen, Inactivated, Cell-Based) NR Australia, Korea, New Zealand, Saudi Arabia, Switzerland FLUAD® Influenza Vaccine Seasonal Trivalent (Surface antigen, Inactivated, Egg Based, Adjuvanted) NI Australia, New Zealand, Taiwan (extension to 50 years+) FLUAD® QUAD/TETRA Influenza Vaccine Seasonal Quadrivalent (Surface antigen, Inactivated, Egg Based, Adjuvanted) NI Australia, New Zealand, Taiwan (extension to 50 years+) FOCLIVIA® Influenza Vaccine Pandemic Monovalent (Subunit, Inactivated, Egg Based, Adjuvanted) NI Switzerland (extension to 6 months+) * First-time registrations or indications for CSL products in the listed countries/regions over the reporting period. 1. FILSPARI® licensed from Travere Therapeutics. 2. In some markets, KORSUVA® is marketed as KAPRUVIA®. KORSUVA®/KAPRUVIA® is a registered trademark of Cara Therapeutics, Inc. Cardiovascular and Renal Improving and extending the lives of patients with cardiovascular and renal diseases PRODUCT TYPE COUNTRY/REGION FERINJECT® Ferric Carboxymaltose NR Moldova (100mg/2mL, 500mg/10mL, 1000mg/20mL), Vietnam (100mg/2mL, 500mg/10mL) FILSPARI® (Sparsentan) Dual ETA & AT1 antagonist (IgAN)1 NR United Arab Emirates KORSUVA® KOR agonist (CKD-aP)2 NR China VELTASSA® Oral Potassium Binder (HK) NR Palestine 17 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3